![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 13
2014
Heublein, Sabine; Mayr, Doris; Friese, Klaus; Jarrin-Franco, Maria Cristina; Lenhard, Miriam; Mayerhofer, Artur und Jeschke, Udo
(September 2014):
The G-Protein-Coupled Estrogen Receptor (GPER/GPR30) in Ovarian Granulosa Cell Tumors.
In: International Journal of Molecular Sciences, Bd. 15, Nr. 9: S. 15161-15172
[PDF, 1MB]
2013
Lenhard, Miriam; Heublein, Sabine; Kunert-Keil, Christiane; Vrekoussis, Thomas; Lomba, Isabel; Ditsch, Nina; Mayr, Doris; Friese, Klaus und Jeschke, Udo
(2013):
Immunosuppressive Glycodelin A is an independent marker for poor prognosis in endometrial cancer.
In: BMC Cancer
13
[PDF, 2MB]
Heublein, Sabine; Grasse, Katinka; Hessel, Harald; Burges, Alexander; Lenhard, Miriam; Engel, Jutta; Kirchner, Thomas; Jeschke, Udo und Mayr, Doris
(2013):
KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.
In: BMC Cancer
13:483
[PDF, 1MB]
Heublein, Sabine; Vrekoussis, Thomas; Mayr, Doris; Friese, Klaus; Lenhard, Miriam; Jeschke, Udo und Dian, Darius
(2013):
Her-2/neu expression is a negative prognosticator in ovarian cancer cases that do not express the follicle stimulating hormone receptor (FSHR).
In: Journal of Ovarian Research
6:6
[PDF, 1MB]
2012
Ditsch, Nina; Toth, Bettina; Mayr, Doris; Lenhard, Miriam; Gallwas, Julia; Weissenbacher, Tobias; Dannecker, Christian; Friese, Klaus und Jeschke, Udo
(2012):
The Association between Vitamin D Receptor Expression and Prolonged Overall Survival in Breast Cancer.
In: Journal of Histochemistry & Cytochemistry, Bd. 60, Nr. 2: S. 121-129
[PDF, 1MB]
Hertlein, Linda; Stieber, Petra; Kirschenhofer, Angela; Fürst, Sophie; Mayr, Doris; Hofmann, Karin; Krocker, Katja; Nagel, Dorothea; Lenhard, Miriam und Burges, Alexander
(2012):
Human epididymis protein 4 (HE4) in benign and malignant diseases.
In: Clinical Chemistry and Laboratory Medicine, Bd. 50, Nr. 12: S. 2181-2188
[PDF, 216kB]
Engelstaedter, Verena; Heublein, Sabine; Schumacher, Anamur Lan; Lenhard, Miriam; Engelstaedter, Helen; Andergassen, Ulrich; Guenthner-Biller, Margit; Kuhn, Christina; Rack, Brigitte; Kupka, Markus; Mayr, Doris und Jeschke, Udo
(2012):
Mucin-1 and its relation to grade, stage and survival in ovarian carcinoma patients.
In: BMC Cancer
12:600
[PDF, 2MB]
Lenhard, Miriam; Tereza, Lennerova; Heublein, Sabine; Ditsch, Nina; Himsl, Isabelle; Mayr, Doris; Friese, Klaus und Jeschke, Udo
(2012):
Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival.
In: BMC Cancer
12:553
[PDF, 1MB]
Lenhard, Miriam; Tsvilina, Alexandra; Schumacher, Lan; Kupka, Markus; Ditsch, Nina; Mayr, Doris; Friese, Klaus und Jeschke, Udo
(2012):
Human chorionic gonadotropin and its relation to grade, stage and patient survival in ovarian cancer.
In: BMC Cancer
12:2
[PDF, 1MB]
Scholz, Christoph; Heublein, Sabine; Lenhard, Miriam; Friese, Klaus; Mayr, Doris und Jeschke, Udo
(2012):
Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients.
In: BMC Research Notes
5:551
[PDF, 2MB]
2011
Lenhard, Miriam; Stieber, Petra; Hertlein, Linda; Kirschenhofer, Angela; Fuerst, Sophie; Mayr, Doris; Nagel, Dorothea; Hofmann, Karin; Krocker, Katja und Burges, Alexander
(2011):
The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
In: Clinical Chemistry and Laboratory Medicine, Bd. 49, Nr. 12: S. 2081-2088
[PDF, 368kB]
2007
Lenhard, Miriam; Kuemper, Caroline; Ditsch, Nina; Diebold, Joachim; Stieber, Petra; Friese, Klaus und Burges, Alexander
(2007):
Use of novel serum markers in clinical follow-up of Sertoli-Leydig cell turnours.
In: Clinical Chemistry and Laboratory Medicine, Bd. 45, Nr. 5: S. 657-661
[PDF, 332kB]
2006
Ditsch, Nina; Rückert, Sandra; Kümper, Carolin; Lenhard, Miriam; Kahlert, Steffen; Bauerfeind, Ingo; Friese, Klaus und Untch, Michael
(2006):
Trastuzumab (Herceptin (R)): Monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation.
In: Breast Care, Nr. 2: S. 78-84
[PDF, 94kB]